• Explore /
  • Poster
  • / Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

Abstract Poster

Authors

Jonathan Kolitz

Jonathan E. Kolitz

Hofstra Northwell School of Medicine, Hempstead, NY

Jonathan E. Kolitz , Stephen Anthony Strickland , Jorge E. Cortes , Donna Hogge , Jeffrey E. Lancet , Stuart L. Goldberg , Karen C Chung , Robert Ryan , Michael Chiarella , Arthur Chin Louie , Robert K. Stuart , Bruno C. Medeiros

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01696084

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7036)

DOI

10.1200/JCO.2017.35.15_suppl.7036

Abstract #

7036

Poster Bd #

236

Abstract Disclosures

Similar Posters

First Author: Ellen K. Ritchie

First Author: Jeffrey E. Lancet

First Author: Jeffrey E. Lancet

First Author: Tara L. Lin